Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 9/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153790 | 1.00 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2RHEB | |
| SCHEMBL31645262 | 1.00 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2RHEB | |
| SCHEMBL17556422 | 0.88 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL19284845 | 0.88 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL10380887 | 0.87 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2HTR2C | |
| SCHEMBL31644626 | 0.87 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2CNR2 | |
| SCHEMBL31645002 | 0.87 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2CNR2 | |
| SCHEMBL22070999 | 0.87 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2HTR2C | |
| SCHEMBL4381700 | 0.87 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2HTR2C | |
| SCHEMBL4381696 | 0.87 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417420-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2023060021-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | MAGNANI JOHN L (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-1601671-B1 | CYCLOALKYL DERIVATIVES COMPRISING BIOISOSTERIC CARBOXYLIC ACID GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-7148246-B2 | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-12-12 | — | — | US | disclosed |
| EP-1601671-A1 | CYCLOALKYL DERIVATIVES COMPRISING BIOISOSTERIC CARBOXYLIC ACID GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-07 | — | — | EP | disclosed |
| EP-1599203-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20040198786-A1 | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| WO-2004076447-A1 | CYCLOALKYL DERIVATIVES COMPRISING BIOISOSTERIC CARBOXYLIC ACID GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004075891-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417420-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC9, SIGLEC7, ASGR1 | SMYD2 3652/4885CYP3A4 2715/4885HTT 4136/4885 |
| US-20040198786-A1 | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals | GPR119, CPT1A, PC | SMYD2 4577/4885CYP3A4 131/4885HTT 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.